Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Relapsed or Refractory Hemangioendothelioma and Vascular Malformations
NCT07477548Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Apr 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of everolimus in hemangioendothelioma, vascular malformation, tufted angioma (TA) and 1 more, sponsored by Yonsei University. Primary endpoint: Overall Response Rate at 6 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
hemangioendotheliomavascular malformationtufted angioma (TA)Kasabach-Merritt syndrome (KMS)
Beyond the preview
Go deeper on NCT07477548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477548.